Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Helen Hancock"'
Autor:
Martin Carby, Jasvir Parmar, Andrew Bryant, Thomas Chadwick, Luke Vale, Catherine Exley, Andrew J Fisher, Helen Hancock, Richard Thompson, Joanne Lally, Andrew R Gennery, Michelle Bardgett, Siân Russell, Michael White, James MS Wason, Nicola Goudie, Anneka Kershaw, Julia Phillipson, Alex Bevin-Nicholls, Hesther Smith, Laura Frisby, Rebecca Errington, Karthik Santhanakrishnan
Publikováno v:
BMJ Open Respiratory Research, Vol 11, Iss 1 (2024)
Background Long-term survival after lung transplantation is limited compared with other organ transplants. The main cause is development of progressive immune-mediated damage to the lung allograft. This damage, which can develop via multiple immune p
Externí odkaz:
https://doaj.org/article/25ff32a40f734970b727cb09b3679576
Autor:
James M. S. Wason, Munyaradzi Dimairo, Katie Biggs, Sarah Bowden, Julia Brown, Laura Flight, Jamie Hall, Thomas Jaki, Rachel Lowe, Philip Pallmann, Mark A. Pilling, Claire Snowdon, Matthew R. Sydes, Sofía S. Villar, Christopher J. Weir, Nina Wilson, Christina Yap, Helen Hancock, Rebecca Maier
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-12 (2022)
Abstract Adaptive designs are a class of methods for improving efficiency and patient benefit of clinical trials. Although their use has increased in recent years, research suggests they are not used in many situations where they have potential to br
Externí odkaz:
https://doaj.org/article/22339b16e2cc4f4288ebaef1419f4518
Autor:
Rebecca Maier, Aislinn Cooper, Robert Chandler, John Marshall, Simon Crabb, Amit Bahl, Ian Pedley, Suneil Jain, John Staffurth, Rob Jones, Rakesh Heer, Paul Gravestock, Miranda Morton, Emma Clark, Holly Fisher, Shirya Sharma, Ruth Wood, Jenn Walker, Nichola Waugh, Helen Hancock
Publikováno v:
NIHR Open Research, Vol 2 (2023)
Background: Prostate cancer is the most commonly diagnosed malignancy in the UK. Castrate resistant prostate cancer (CRPC) can be difficult to manage with response to next generation hormonal treatment variable. AR-V7 is a protein biomarker that can
Externí odkaz:
https://doaj.org/article/3d23599209254e9d8aff6029a8adb3e8
Autor:
Nina Wilson, Katie Biggs, Sarah Bowden, Julia Brown, Munyaradzi Dimairo, Laura Flight, Jamie Hall, Anna Hockaday, Thomas Jaki, Rachel Lowe, Caroline Murphy, Philip Pallmann, Mark A. Pilling, Claire Snowdon, Matthew R. Sydes, Sofía S. Villar, Christopher J. Weir, Jessica Welburn, Christina Yap, Rebecca Maier, Helen Hancock, James M. S. Wason
Publikováno v:
BMC Medicine, Vol 19, Iss 1, Pp 1-17 (2021)
Abstract Background Adaptive designs offer great promise in improving the efficiency and patient-benefit of clinical trials. An important barrier to further increased use is a lack of understanding about which additional resources are required to con
Externí odkaz:
https://doaj.org/article/54a6d8a22728449aaca970ea965fdb82
Autor:
Alison J. Moskowitz, Gunjan Shah, Heiko Schöder, Nivetha Ganesan, Helen Hancock, Theresa Davey, Leslie Perez, Samia Sohail, Alayna Santarosa, Charisse Capadona, Brittney Munayirji, Anita Kumar, Oscar Lahoud, Connie Batlevi, Paul Hamlin, David J. Straus, Colette Owens, Philip Caron, Andrew Intlekofer, Audrey Hamilton, Steven Horwitz, Lorenzo Falchi, William Johnson, Lia Palomba, Ariela Noy, Matthew Matasar, Georgios Pongas, Gilles Salles, Santosha Vardhana, Beatriz Wills Sanin, Joachim Yahalom, Ahmet Dogan, Andrew Zelenetz, Craig H. Moskowitz
Publikováno v:
HemaSphere, Vol 6, Pp 45-46 (2022)
Externí odkaz:
https://doaj.org/article/c3f78da76e2d4f44be43c41df7fd8c16
Autor:
Beatriz Wills, Nivetha Ganesan, Gunjan L. Shah, Phillip Wong, Kimon V. Argyropoulos, Filiz Sen, Ahmet Dogan, David J. Straus, Ariela Noy, Anita Kumar, Heiko Schoder, Laure Michaud, Maria Lia Palomba, Lorenzo Falchi, Oscar B Lahoud, Paul A. Hamlin, Joachim Yahalom, William T. Johnson, Andrew D. Zelenetz, Andrew M. Intlekofer, Colette Owens, Connie Lee Batlevi, Audrey Hamilton, Philip C Caron, Steven M. Horwitz, Natasha Galasso, Helen Hancock, Theresa Davey, Alayna Santarosa, Leslie Perez, Charisse Capadona, Brittney Munayirji, Matthew J. Matasar, Georgios Pongas, Ellie Casper, Gilles Salles, Craig H. Moskowitz, Santosha Vardhana, Alison J. Moskowitz
Publikováno v:
Blood. 140:9286-9288
Autor:
Pyotr Telyuk, Helen Hancock, Rebecca Maier, Jonathan A Batty, Andrew Goodwin, W Andrew Owens, Emmanuel Ogundimu, Enoch Akowuah
Publikováno v:
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 63(1)
OBJECTIVES Aortic valve replacement (AVR) for severe symptomatic aortic stenosis is one of the most common cardiac surgical procedures with excellent long-term outcomes. Multiple previous studies have compared short-term outcomes of AVR with mini-ste
Autor:
Paul Gravestock, Emma Clark, Miranda Morton, Shirya Sharma, Holly Fisher, Jenn Walker, Ruth Wood, Helen Hancock, Nichola Waugh, Aislinn Cooper, Rebecca Maier, John Marshall, Robert Chandler, Amit Bahl, Simon Crabb, Suneil Jain, Ian Pedley, Rob Jones, John Staffurth, Rakesh Heer
Publikováno v:
NIHR Open Research. 2:49
Background: Prostate cancer is the most commonly diagnosed malignancy in the UK. Castrate resistant prostate cancer (CRPC) can be difficult to manage with response to next generation hormonal treatment variable. AR-V7 is a protein biomarker that can
Autor:
Brielle Liotta, Natasha Galasso, Lauren Pomerantz, Jürgen Rademaker, Esther Drill, Ahmet Dogan, Jeeyeon Baik, Heiko Schöder, Steven M. Horwitz, Leslie Perez, William Blouin, Theresa Davey, Obadi Obadi, Giorgio Inghirami, Eric D. Jacobsen, Jonathan H. Schatz, Mark B. Geyer, Ariela Noy, Jack Dowd, Santosha A. Vardhana, David J. Straus, Nancy Yi, Sarah J. Noor, David M. Weinstock, Travis J. Hollmann, Helen Hancock, Priyadarshini Kumar, Nivetha Ganesan, Paola Ghione, Jia Ruan, Alison J. Moskowitz, Rachel Neuman, Alayna Santarosa, Sunyoung Ryu, Patricia L. Myskowski, Samia Sohail
Publikováno v:
Blood
Signaling through JAK1 and/or JAK2 is common among tumor and nontumor cells within peripheral T-cell lymphoma (PTCL). No oral therapies are approved for PTCL, and better treatments for relapsed/refractory disease are urgently needed. We conducted a p
Autor:
Ahmet Dogan, Heiko Schöder, Oscar B Lahoud, Santosha Vardhana, Theresa Davey, Craig H. Moskowitz, Anita Kumar, M. Lia Palomba, Brielle Liotta, Paul A. Hamlin, Beatriz Wills Sanin, Colette Owens, William T. Johnson, Joachim Yahalom, Matthew J. Matasar, Connie Lee Batlevi, Christina R. Lee, Alayna Santarosa, Helen Hancock, Lorenzo Falchi, Esther Drill, Audrey Hamilton, Alison J. Moskowitz, Samia Sohail, Rachel Neuman, Gunjan L. Shah, Sunyoung Ryu, Natasha Galasso, David J. Straus, Gilles Salles, Georgios Pongas, William Blouin, Steven M. Horwitz, Ariela Noy, Erel Joffe, Ildefonso Rodriguez-Rivera, Andrew D. Zelenetz, Andrew M. Intlekofer, Gottfried von Keudell, Nivetha Ganesan, Philip Caron, Leslie Perez
Publikováno v:
J Clin Oncol
PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov iden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9666753bc8fb50bed83326e0a6db7606
https://europepmc.org/articles/PMC9851707/
https://europepmc.org/articles/PMC9851707/